China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Capital Reinvestment Ratio
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Capital Reinvestment Ratio of 0.39x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥487.90 Million) in capital expenditures (CN¥192.28 Million). Check China Resources Double-Crane Pharmaceuti tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China Resources Double-Crane Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2024)
This chart tracks China Resources Double-Crane Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. For the full cash flow conversion analysis, see 600062 cash flow conversion.
Annual Capital Reinvestment Ratio for China Resources Double-Crane Pharmaceutical Co Ltd (1999–2024)
Year-by-year Capital Reinvestment Ratio for China Resources Double-Crane Pharmaceutical Co Ltd from 1999 to 2024. See 600062 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | CN¥1.83 Billion | CN¥637.50 Million | ▼ -6.1% |
| 2023 | 0.37x | CN¥1.65 Billion | CN¥614.31 Million | ▼ -5.0% |
| 2022 | 0.39x | CN¥1.34 Billion | CN¥525.53 Million | ▲ +6.8% |
| 2021 | 0.37x | CN¥1.34 Billion | CN¥491.67 Million | ▲ +43.3% |
| 2020 | 0.26x | CN¥1.36 Billion | CN¥348.09 Million | ▲ +52.5% |
| 2019 | 0.17x | CN¥1.44 Billion | CN¥241.65 Million | ▲ +7.8% |
| 2018 | 0.16x | CN¥1.47 Billion | CN¥228.69 Million | ▲ +19.4% |
| 2017 | 0.13x | CN¥1.19 Billion | CN¥154.82 Million | ▼ -8.6% |
| 2016 | 0.14x | CN¥771.25 Million | CN¥110.04 Million | ▼ -40.6% |
| 2015 | 0.24x | CN¥701.35 Million | CN¥168.49 Million | ▲ +21.2% |
| 2014 | 0.20x | CN¥718.38 Million | CN¥142.38 Million | ▼ -50.3% |
| 2013 | 0.40x | CN¥546.24 Million | CN¥217.68 Million | ▼ -28.9% |
| 2012 | 0.56x | CN¥396.05 Million | CN¥221.89 Million | ▼ -15.4% |
| 2011 | 0.66x | CN¥511.53 Million | CN¥338.78 Million | ▼ -8.8% |
| 2010 | 0.73x | CN¥509.67 Million | CN¥370.18 Million | ▼ -12.9% |
| 2009 | 0.83x | CN¥342.01 Million | CN¥285.16 Million | ▼ -10.6% |
| 2008 | 0.93x | CN¥331.71 Million | CN¥309.20 Million | ▲ +61.2% |
| 2007 | 0.58x | CN¥235.46 Million | CN¥136.17 Million | ▲ +2.3% |
| 2006 | 0.57x | CN¥303.71 Million | CN¥171.66 Million | ▼ -37.9% |
| 2005 | 0.91x | CN¥139.78 Million | CN¥127.13 Million | ▲ +109.7% |
| 2004 | 0.43x | CN¥453.72 Million | CN¥196.84 Million | ▼ -82.8% |
| 2003 | 2.52x | CN¥148.94 Million | CN¥375.98 Million | ▲ +40.9% |
| 2002 | 1.79x | CN¥140.63 Million | CN¥251.99 Million | ▲ +43.9% |
| 2001 | 1.25x | CN¥141.01 Million | CN¥175.58 Million | ▲ +147.8% |
| 2000 | 0.50x | CN¥172.81 Million | CN¥86.83 Million | ▼ -5.4% |
| 1999 | 0.53x | CN¥131.54 Million | CN¥69.86 Million | — |